Advertisement
Advertisement
U.S. markets open in 9 hours 30 minutes
S&P Futures
4,153.25 +11.50 (+0.28%) Dow Futures
32,877.00 +85.00 (+0.26%) Nasdaq Futures
13,220.50 +37.25 (+0.28%) Russell 2000 Futures
1,947.10 +6.00 (+0.31%) Crude Oil
90.63 -0.13 (-0.14%) Gold
1,786.40 -0.40 (-0.02%)
Tetra Bio-Pharma Inc. (TBPMF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 12:20PM EDT
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.0468 |
| Open | 0.0485 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0485 - 0.0485 |
| 52 Week Range | 0.0372 - 0.2740 |
| Volume | |
| Avg. Volume | 71,659 |
| Market Cap | 22.198M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0840 |
| Earnings Date | Jul 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- TETRA BIO PHARMA INCAnalyst Report: Canopy Growth CorporationCanopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.RatingFair ValueEconomic Moat3 days agoMorningstar
- Business Wire
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
LONDON & MONTREAL, July 12, 2022--Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form for global commercialization of Tetra’s QIXLEEF.
- PR Newswire
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
